Repeated direct fetal intravascular high-dose immunoglobulin therapy for the treatment of Rh hemolytic disease.
Recently, administration of high-dose intravenous immunoglobulin (HDivIG) either to the mother or the neonate has been proposed in an effort to prevent progressive hemolysis in Rh(D) perinatal disease, but no cases have been published with direct fetal HDivIG administration. We report a case in which HDivIG was repeatedly administered by cordocentesis to a fetus affected by Rh(D) disease from 28 to 36 weeks gestation, at doses of approximately 450 mg/kg. The fetus required no transfusions, and the neonatal evolution was satisfactory. The treatment, performed at three weeks intervals, seemed to be useful in preventing fetal hemolysis. No fetal complications were present. Recurrent administration of HDivIG therapy to the fetus in cases of severe Rh(D) disease, appears to be feasible and free of serious complications to the fetus or the mother.
Alonso
J G
JG
Department of Obstetrics and Gynecology, Hospital De Clinicas, Montevideo School of Medicine, University of Uruguay.
Decaro
J
J
Marrero
A
A
Lavalle
E
E
Martell
M
M
Cuadro
J C
JC
D000328:Adult; D004334:Drug Administration Schedule; D004899:Erythroblastosis, Fetal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007231:Infant, Newborn; D008297:Male; D011247:Pregnancy; D011295:Prenatal Care / Q000379:methods*
D016756:Immunoglobulins, Intravenous